Le réseau Unicancer à l’ASCO 2022

Les équipes scientifiques et médicales d’Unicancer, unique réseau hospitalier français dédié à 100% à la lutte contre le cancer, ont presenté les résultats de leurs recherches à l’occasion du congrès de l’American Society of Clinical Oncology (ASCO) du 3 au 7 juin 2022, qui s’est déroulé en présentiel à Chicago, Etats-Unis.

Unicancer est promoteur académique et opérateur de recherches cliniques en cancérologie. Son département R&D travaille étroitement avec les unités de recherche des Centres de lutte contre le cancer et les autres établissements de santé (CHU, CH, cliniques…), en France et à l’international. La Recherche & Développement d’Unicancer est à la pointe de la recherche en oncologie en plaçant l’innovation au cœur de sa mission. Son activité est organisée autour de trois grands thèmes : la recherche clinique, la recherche translationnelle et les données médicales de vraie vie.

Press Room Virtuelle Unicancer

---

Les travaux présentés par le département R&D d’Unicancer

Présentations orales

GERICO – Dialog, Intergroupe pour la personnalisation de la prise en charge en oncogériatrie

Étude GERICO 11 / ASTER 70s, Discussion le 7 juin 2022, 9:45 AM-12:45 PM CDT, Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial, E. Brain, Abstract #500

Posters

Le Groupe d’Immuno-Oncologie d’Unicancer

• Étude MOIO, A non-inferiority randomized phase III trial of standard immunotherapy VS. reduced dose intensity in responding patients with metastatic cancer: the MOIO study, G. Gravis, D. Olive, P. Marino, F. Penault-LLorca, J.-P. Delord, A. Lamrani-Ghaouti, C. Simon, R. Sabatier, J. Ciccolini, J.-M. Boher
• Étude AcSé Pembrolizumab, Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma and other rare ovarian tumor histotypes: the French AcSé Pembrolizumab study from Unicancer, I. Ray-Coquard, N. Penel, E. Bompas, E. Coquan, P. Soulie, S. Cousin, F. Bertucci, D. Tosi, P.-E. Heudel, C. Abdeddaim, P. Pautier, E. Kalbacher, F. Selle, A. Floquet, l. Gambotti, C. Simon, A. Lamrani-ghaouti, S. Chevret, C. Even

UCBG – French Breast Cancer Intergroup Unicancer

Étude DOLAF, DOLAF- An international multicenter phase I/II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib, S. Guiu

GETUG – Groupe d’Etude des Tumeurs UroGénitales

Étude NIVOREN, Baseline circulating soluble factors as predictors of response to nivolumab in metastatic clear cell renal cell carcinoma (mRCC): A validation study within the NIVOREN GETUG-AFU 26 translational study, L. Carril, M. Naigeon, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C. Sautes-Fridman, M. Meylan, Y.-A. Vano, B. Beusenlick, S. Chouaib, C. de Oliveira, F. Tantot, B. Escudier, L. Albiges, N. Chaput

Chiffres clés du département R&D d’Unicancer

---

Les travaux présentés par les Centres du réseau Unicancer

Présentations orales / discussions des posters

• Cancers génito-urinaires : Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial., P. Barthélémy, ICANS, Strasbourg
• Oncologie pédiatrique : Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE), P. Berlanga et G. Vassal, Gustave Roussy, Villejuif
• Session éducative : The Impact of Current Kidney Function Estimators on Modern Cancer Therapy, F. Thomas Jean, IUCT Oncopole – Institut Claudius Régaud, Toulouse
• Symposium de science clinique « Bispecifics: Are Two Better Than One? » : Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial, L. Albigès, Gustave Roussy, Villejuif
• Symposium de science clinique « ctDNA: Dawn of a New Era » : Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100, J-P Delord, IUCT Oncopole – Institut Claudius Régaud, Toulouse
• Tumeurs hématologiques : Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial, S. De Botton, Gustave Roussy, Villejuif
• Cancer gastro-intestinal :
  • Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial, A. Adenis, Institut du Cancer de Montpellier
  • Contact x-ray brachytherapy (Papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2-T3 rectal adenocarcinoma: The 3-year results of OPERA randomized trial (NCT02505750), J.-P. Gerard, Centre Antoine Lacassagne, Nice
• Thérapeutique du développement :
  • Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results, Y. Loriot, Gustave Roussy, Villejuif
  • Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors, C. Gomez-Roca, IUCT Oncopole, Toulouse
  • Identifying mechanisms of acquired immune escape from sequential, paired biopsies, C. Gomez-Roca, IUCT Oncopole, Toulouse

Posters

Cancer du poumon :

• Efficacy of dabrafenib-trametinib combination in BRAF V600E-mutated metastatic non–small cell lung cancer: Results of the IFCT-2004 BLaDE cohort, A. Swalduz, Centre Léon Bérard, Lyon
• Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial, B. Besse, Gustave Roussy, Villejuif et A. Madroszyk, Institut Paoli Calmettes, Marseille
• GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial, F. Ghiringhelli, Centre Georges Francois Leclerc, Dijon

Cancer du sein :

• DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib, S. G. Lahaye, Institut du Cancer de Montpellier
• Subgroup analysis of patients with no prior chemotherapy in EMERALD: a phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC), F. Dalenc, IUCT Oncopole, Toulouse

Sarcomes :

• Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts, M.-C. Le Deley, Centre Oscar Lambret, Lille, J.-Y. Blay, Centre Léon Bérard, Lyon, C. Chevreau, IUCT Oncopole, Toulouse
• PEC-PRO: A new prognostic score from a series of 93 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent, J. Gantzer, ICANS, Strasbourg et V. Thibaud, IUCT Oncopole, Toulouse
• REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment, M. Brahmi, Centre Léon Bérard, Lyon et V. Thibaud, IUCT Oncopole, Toulouse

Cancers gynécologiques :

• Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644), J. E. Kurtz, ICANS, Strasbourg
• Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer, I. L. Ray-Coquard, Centre Léon Bérard, Lyon
• Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial, F. Joly, Centre François Baclesse, Caen

Cancers génito-urinaires :

• Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC), A. Bernard-Tessier, Gustave Roussy, Villejuif et P. Barthélémy, ICANS, Strasbourg

Cancer gastro-intestinal :

• Do we need postoperative chemotherapy after preoperative FOLFIRINOX in resected borderline or locally advanced pancreatic cancer? A retrospective analysis, R. Mari, A. Gonçalves et P. Rochigneux, Institut Paoli Calmettes, Marseille
• Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study, A. Adenis, Institut du Cancer de Montpellier
• Sequential treatment with gemcitabine/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial, F. Portales, E. Samalin, Institut du Cancer de Montpellier
• Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial, F. Portales, E. Samalin, Institut du Cancer de Montpellier
• REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort, C. Gomez-Roca, IUCT Oncopole, Toulouse
• REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort, C. Gomez-Roca, IUCT Oncopole – Institut Claudius Régaud, Toulouse

Tumeurs hématologiques :

• Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results, P. Bories, IUCT Oncopole – Institut Claudius Régaud, Toulouse
• Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study, T. Faucon, IUCT Oncopole – Institut Claudius Régaud, Toulouse

Thérapeutique du développement :

• Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC), J-P Delord, IUCT Oncopole – Institut Claudius Régaud, Toulouse
• Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized phase II trial, O. Tredan, Centre Léon Bérard, Lyon et C. Gomez-Roca, IUCT Oncopole, Toulouse
• Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in solid tumors: Data-mining of 1,382 electronic patient records, M. Beaufils, A. Gonçalves, P. Rochigneux et A. Madroszyk, Institut Paoli Calmettes, Marseille
• A non-inferiority randomized phase III trial of standard immunotherapy versus reduced dose intensity in responding patients with metastatic cancer: MOIO study, G. Gravis, Institut Paoli Calmettes, Marseille
• Adaptive response analysis of colorectal cancer cells to low-dose oxaliplatin as a tool to deciphering mechanisms of synergistic drug interaction, D. Tosi, Institut du Cancer de Montpellier